Table 1.
Basic characteristics of the included trials.
| Study | Patients (n) | Sex (male/female) | Diagnostic standard | |
|---|---|---|---|---|
| Experimental group/control group | Experimental group | Control group | ||
| Peifeng, 2015 [15] | 33/33 | 21/12 | C:21/12 | NR |
| Xiaofei et al., 2016 [16] | 40/40 | 22/18 | 20/20 | GPTH2010 and GPCREDTCM |
| Tao, 2016 [17] | 61/61 | 22/18 | 20/20 | GPTH2010 and CMDDES |
| Yingke, 2014 [18] | 60/60 | 32/28 | 33/27 | GPCREDTCM |
| Jinbo, 2015 [19] | 154/153 | 87/67 | 75/78 | NR |
| Fan and Lili, 2015 [20] | 30/30 | NR | NR | CMDTHDESN |
| Pan, 2019 [21] | 52/52 | 26/26 | 25/27 | NR |
| Xiaofang, 2016 [22] | 55/55 | 30/25 | 32/23 | GPTH2010 |
| Fu, 2018 [23] | 40/40 | 22/18 | 24/16 | GPTH2010 |
| Caihong, 2017 [24] | 40/40 | 5/15 | 23/17 | GPTH2010 and GPCREDTCM |
| Dai, 2019 [25] | 55/55 | NR | NR | NR |
| Yugao, 2017 [26] | 23/23 | 14/9 | 13/10 | GPCREDTCM |
| Peng et al., 2016 [27] | 46/46 | 25/21 | 26/20 | NR |
| Yingjun, 2015 [28] | 80/80 | 48/32 | 46/34 | GPTH2010 and GPCREDTCM |
Note: NR: no report; GPTH2010: Guide to Prevention and Treatment of Hypertension 2010; GPCREDTCM: Guiding Principles for Clinical Research of New Drugs in Traditional Chinese Medicine; CMDDES: Chinese Medicine Dialectical Diagnosis Efficacy Standard; CMDTHDESN: Chinese Medicine Diagnosis and Treatment of Heart Disease Efficacy Standards and Norms; GPTHC: Guide to Prevention and Treatment of Hypertension in China (trial version).